Glucose-induced Glucagon-like Peptide 1 (GLP-1) Secretion in NAFLD Patients Compared to Healthy Controls

University Hospital Basel

Status: Completed

Conditions: Non Alcoholic Steatohepatitis; Non Alcoholic Fatty Liver Disease

Treatments: Other: Oral glucose tolerance test

Study type: Observational

Funder types: Other

Identifiers

NCT01674972

EKBB 224/02.2

Details and patient eligibility

About

The incretin effect is impaired in patients with type 2 diabetes mellitus (T2DM), thus GLP-1 receptor agonists are used for the treatment of T2DM. Insulin resistance is a pathophysiologic hallmark of non-alcoholic fatty liver disease (NAFLD). The incretin effect in patients with NAFLD has not been studied. The aim of this study is to quantify GLP-1 secretion in response to oral glucose tolerance test (oGTT) in patients with NAFLD compared to healthy controls. The results of this study will expand the knowledge of the pathophysiology of NAFLD and serve as a rational for potential future treatment strategies.

Full description

Primary endpoint: GLP-1 response to oral glucose Secondary endpoints: glucose and insulin responses to oral glucose challenge

Enrollment: 102 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Biopsy proven NAFLD or NASH

Exclusion criteria

• additional concomitants liver disease
• T2DM
• alcohol consumption >40g/d for male subjects and >20g/d for female subjects

Trial design

102 participants in 2 patient groups

NAFLD

Description:

Patients with biopsy proven NAFLD

Treatment:

Other: Oral glucose tolerance test

Control

Description:

Matched healthy control subjects

Treatment:

Other: Oral glucose tolerance test